Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation
PLoS biology, 2022-02, Vol.20 (2), p.e3001547-e3001547 [Peer Reviewed Journal]2022 Richardson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 Richardson et al 2022 Richardson et al ;ISSN: 1545-7885 ;ISSN: 1544-9173 ;EISSN: 1545-7885 ;DOI: 10.1371/journal.pbio.3001547 ;PMID: 35213538
Full text available